Literature DB >> 31401152

Nephrolithiasis and sodium-glucose co-transporter-2 (SGLT-2) inhibitors: A meta-analysis of randomized controlled trials.

Claudia Cosentino1, Ilaria Dicembrini1, Besmir Nreu1, Edoardo Mannucci1, Matteo Monami2.   

Abstract

Sodium-glucose cotransporter 2 inhibitors (SGLT2i) decreased serum uric acid in type 2 diabetes. Hyperuricemia is associated with an increased risk of nephrolithiasis. The present meta-analysis, performed on trials with duration ≥52 weeks in comparison with placebo or active comparators, suggests no effects of SGLT-2i on the risk of nephrolithiasis.
Copyright © 2019 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Hyperuricemia; Meta-analysis; Nephrolithiasis; SGLT-2 inhibitors

Mesh：

Substances：

Year:  2019        PMID： 31401152     DOI： 10.1016/j.diabres.2019.107808

Source DB:  PubMed          Journal:  Diabetes Res Clin Pract        ISSN： 0168-8227            Impact factor:   5.602


  4 in total

1.  Factors Influencing Change in Serum Uric Acid After Administration of the Sodium-Glucose Cotransporter 2 Inhibitor Luseogliflozin in Patients With Type 2 Diabetes Mellitus.

Authors:  Yukihiro Chino; Masanari Kuwabara; Ichiro Hisatome
Journal:  J Clin Pharmacol       Date:  2021-11-19       Impact factor: 2.860

2.  Sodium-glucose cotransporter 2 inhibitors and risk of nephrolithiasis.

Authors:  Kasper B Kristensen; Daniel P Henriksen; Jesper Hallas; Anton Pottegård; Lars C Lund
Journal:  Diabetologia       Date:  2021-03-13       Impact factor: 10.122

3.  A Description of Acute Renal Failure and Nephrolithiasis Associated With Sodium-Glucose Co-Transporter 2 Inhibitor Use: A VigiBase Study.

Authors:  Ioana Frent; Daniel Leucuta; Camelia Bucsa; Andreea Farcas; Florin Casoinic; Cristina Mogosan
Journal:  Front Pharmacol       Date:  2022-08-08       Impact factor: 5.988

Review 4.  A Role for SGLT-2 Inhibitors in Treating Non-diabetic Chronic Kidney Disease.

Authors:  Lucia Del Vecchio; Angelo Beretta; Carlo Jovane; Silvia Peiti; Simonetta Genovesi
Journal:  Drugs       Date:  2021-08-07       Impact factor: 9.546
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.